82 results on '"Ballanger B"'
Search Results
2. Imagerie des signes non moteurs dans la maladie de Parkinson
- Author
-
Thobois, S., Ballanger, B., Poisson, A., and Broussolle, E.
- Published
- 2012
- Full Text
- View/download PDF
3. Pre-stimulus activity within the medial fronto-parietal network predicts impulsivity in PD patients treated with STN-DBS: 1188
- Author
-
Favre, E., Lio, G., Albares, M., Thobois, S., Broussolle, E., Ballanger, B., and Boulinguez, P.
- Published
- 2014
4. Noradrenergic modulation of movement initiation control in Parkinsonʼs disease: A pharmacological fMRI study with clonidine: 347
- Author
-
Ballanger, B., Criaud, M., Poisson, A., Metereau, E., Redouté, J., Ibarrola, D., Broussolle, E., Thobois, S., and Boulinguez, P.
- Published
- 2014
5. Noradrenergic modulation of movement initiation control in Parkinsonʼs disease: 344
- Author
-
Albares, M., Thobois, S., Favre, E., Broussolle, E., Boulinguez, P., and Ballanger, B.
- Published
- 2014
6. Motor urgency is mediated by the contralateral cerebellum in Parkinson's disease
- Author
-
Ballanger, B., Baraduc, P., Broussolle, E., Le Bars, D., Desmurget, M., and Thobois, S.
- Subjects
Parkinson's disease -- Development and progression ,Parkinson's disease -- Research ,Motor ability -- Research ,Cerebellum -- Physiological aspects ,Cerebellum -- Research ,Health ,Psychology and mental health - Published
- 2008
7. Perceptual factors contribute to akinesia in Parkinson’s disease
- Author
-
Ballanger, B., Gil, R., Audiffren, M., and Desmurget, M.
- Published
- 2007
- Full Text
- View/download PDF
8. Increased dopamine release in the right anterior cingulate cortex during the performance of a sorting task: a [11C]FLB 457 PET study
- Author
-
Ko, J H, Ptito, A, Monchi, O, Cho, S S, Van Eimeren, T, Pellechia, G, Ballanger, B, Rusjan, P, Houle, S, and Strafella, A P
- Published
- 2009
- Full Text
- View/download PDF
9. Release your horses: Deep Brain Stimulation of the subthalamic nucleus improves motor functions at the expense of response inhibition. A H215O PET study.
- Author
-
Ballanger, B, van Eimeren, T, Moro, E, Lozano, A M, Hamani, C, Boulinguez, P, Pellechia, G, Houle, S, Poon, Y Y, Lang, A E, and Strafella, A
- Published
- 2009
- Full Text
- View/download PDF
10. Dopamine Agonists shift reward system to “addiction mode”. High-phasic activity, abolished reward rating in the orbitofrontal cortex and increased risk taking.
- Author
-
van Eimeren, T, Ballanger, B, Pellecchia, G, Miyasaki, J, Lang, A E, and Strafella, A P
- Published
- 2009
- Full Text
- View/download PDF
11. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD.
- Author
-
van Eimeren T, Pellecchia G, Cilia R, Ballanger B, Steeves TD, Houle S, Miyasaki JM, Zurowski M, Lang AE, Strafella AP, van Eimeren, T, Pellecchia, G, Cilia, R, Ballanger, B, Steeves, T D L, Houle, S, Miyasaki, J M, Zurowski, M, Lang, A E, and Strafella, A P
- Published
- 2010
- Full Text
- View/download PDF
12. Contact dependent reproducible hypomania induced by deep brain stimulation in Parkinson's disease: clinical, anatomical and functional imaging study
- Author
-
Ulla, M., primary, Thobois, S., additional, Llorca, P.-M., additional, Derost, P., additional, Lemaire, J.-J., additional, Chereau-Boudet, I., additional, de Chazeron, I., additional, Schmitt, A., additional, Ballanger, B., additional, Broussolle, E., additional, and Durif, F., additional
- Published
- 2010
- Full Text
- View/download PDF
13. P1.105 rCBF changes associated with pathological gambling in Parkinson's disease: a H215O PET study
- Author
-
Van Eimeren, T., primary, Pellecchia, G., additional, Miyasaki, J., additional, Ballanger, B., additional, Steeves, T., additional, Houle, S., additional, Lang, A., additional, and Strafella, A., additional
- Published
- 2009
- Full Text
- View/download PDF
14. Perceptual factors contribute to akinesia in Parkinson’s disease
- Author
-
Ballanger, B., primary, Gil, R., additional, Audiffren, M., additional, and Desmurget, M., additional
- Published
- 2006
- Full Text
- View/download PDF
15. Deep brain stimulation of the subthalamic nucleus, but not dopaminergic medication, improves proactive inhibitory control of movement initiation in Parkinson's disease.
- Author
-
Favre E, Ballanger B, Thobois S, Broussolle E, Boulinguez P, Favre, Emilie, Ballanger, Bénédicte, Thobois, Stéphane, Broussolle, Emmanuel, and Boulinguez, Philippe
- Abstract
Slowness in movement initiation is a cardinal feature of Parkinson's disease (PD) that is still poorly understood and unsuccessfully alleviated by standard therapies. Here, we raise this major clinical issue within the framework of a novel theoretical model that allows a better understanding of the basic mechanisms involved in movement initiation. This model assumes that movement triggering is inhibited by default to prevent automatic responses to unpredictable events. We investigated to which extent the top-down control necessary to release this locking state before initiating actions is impaired in PD and restored by standard therapies. We used a cue-target reaction time task to test both the ability to initiate fast responses to targets and the ability to refrain from reacting to cues. Fourteen patients with dopaminergic (DA) medication and 11 with subthalamic nucleus (STN) stimulation were tested on and off treatment, and compared with 14 healthy controls. We found evidence that patients withdrawn from treatment have trouble voluntarily releasing proactive inhibitory control; while DA medication broadly reduces movement initiation latency, it does not reinstate a normal pattern of movement initiation; and stimulation of the STN specifically re-establishes the efficiency of the top-down control of proactive inhibition. These results suggest that movement initiation disorders that resist DA medication are due to executive, not motor, dysfunctions. This conclusion is discussed with regard to the role the STN may play as an interface between non-DA executive and DA motor systems in cortico-basal ganglia loops. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
16. P1.105 rCBF changes associated with pathological gambling in Parkinson's disease: a H 215O PET study
- Author
-
Van Eimeren, T., Pellecchia, G., Miyasaki, J., Ballanger, B., Steeves, T., Houle, S., Lang, A., and Strafella, A.
- Published
- 2009
- Full Text
- View/download PDF
17. P1.105 rCBF changes associated with pathological gambling in Parkinson's disease: a H215O PET study
- Author
-
Van Eimeren, T., Pellecchia, G., Miyasaki, J., Ballanger, B., Steeves, T., Houle, S., Lang, A., and Strafella, A.
- Published
- 2009
- Full Text
- View/download PDF
18. Noradrenergic alterations in Parkinson's disease: a combined 11C-yohimbine PET/neuromelanin MRI study.
- Author
-
Laurencin C, Lancelot S, Brosse S, Mérida I, Redouté J, Greusard E, Lamberet L, Liotier V, Le Bars D, Costes N, Thobois S, Boulinguez P, and Ballanger B
- Subjects
- Humans, Tremor complications, Carbon Radioisotopes metabolism, Positron-Emission Tomography, Norepinephrine metabolism, Locus Coeruleus metabolism, Magnetic Resonance Imaging, Parkinson Disease metabolism, Melanins
- Abstract
Degeneration of the noradrenergic system is now considered a pathological hallmark of Parkinson's disease, but little is known about its consequences in terms of parkinsonian manifestations. Here, we evaluated two aspects of the noradrenergic system using multimodal in vivo imaging in patients with Parkinson's disease and healthy controls: the pigmented cell bodies of the locus coeruleus with neuromelanin sensitive MRI; and the density of α2-adrenergic receptors (ARs) with PET using 11C-yohimbine. Thirty patients with Parkinson's disease and 30 age- and sex-matched healthy control subjects were included. The characteristics of the patients' symptoms were assessed using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Patients showed reduced neuromelanin signal intensity in the locus coeruleus compared with controls and diminished 11C-yohimbine binding in widespread cortical regions, including the motor cortex, as well as in the insula, thalamus and putamen. Clinically, locus coeruleus neuronal loss was correlated with motor (bradykinesia, motor fluctuations, tremor) and non-motor (fatigue, apathy, constipation) symptoms. A reduction of α2-AR availability in the thalamus was associated with tremor, while a reduction in the putamen, the insula and the superior temporal gyrus was associated with anxiety. These results highlight a multifaceted alteration of the noradrenergic system in Parkinson's disease since locus coeruleus and α2-AR degeneration were found to be partly uncoupled. These findings raise important issues about noradrenergic dysfunction that may encourage the search for new drugs targeting this system, including α2-ARs, for the treatment of Parkinson's disease., (© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.)
- Published
- 2024
- Full Text
- View/download PDF
19. Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson's disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial.
- Author
-
Laurencin C, Timestit N, Marques A, Duchez DD, Giordana C, Meoni S, Huddlestone M, Danaila T, Anheim M, Klinger H, Vidal T, Fatisson M, Caire C, Nourredine M, Boulinguez P, Dhelens C, Ballanger B, Prange S, Bin S, and Thobois S
- Subjects
- Humans, Clonidine adverse effects, Impulsive Behavior, Double-Blind Method, Treatment Outcome, Parkinson Disease complications, Parkinson Disease drug therapy, Parkinson Disease diagnosis, Disruptive, Impulse Control, and Conduct Disorders drug therapy, Disruptive, Impulse Control, and Conduct Disorders etiology
- Abstract
Background: Impulse control disorders (ICDs) are frequently encountered in Parkinson's disease (PD)., Objectives: We aimed to assess whether clonidine, an α2-adrenergic receptor agonist, would improve ICDs., Methods: We conducted a multicentre trial in five movement disorder departments. Patients with PD and ICDs (n = 41) were enrolled in an 8-week, randomised (1:1), double-blind, placebo-controlled study of clonidine (75 μg twice a day). Randomisation and allocation to the trial group were carried out by a central computer system. The primary outcome was the change at 8 weeks in symptom severity using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) score. A reduction of the most elevated subscore of the QUIP-RS of more than 3 points without any increase in the other QUIP-RS dimension defined success., Results: Between 15 May 2019 and 10 September 2021, 19 patients in the clonidine group and 20 patients in the placebo group were enrolled. The proportion difference of success in reducing QUIP-RS at 8 weeks, was 7% (one-sided upper 90% CI 27%) with 42.1% of success in the clonidine group and 35.0% in the placebo group. Compared to patients in the placebo group, patients in the clonidine group experienced a greater reduction in the total QUIP-RS score at 8 weeks (11.0 points vs. 3.6)., Discussion: Clonidine was well tolerated but our study was not enough powerful to demonstrate significant superiority compared to placebo in reducing ICDs despite a greater reduction of total QUIP score at 8 weeks. A phase 3 study should be conducted., Trial Registration: The study was registered (NCT03552068) on clinicaltrials.gov on June 11, 2018., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
20. Distribution of α 2 -Adrenergic Receptors in the Living Human Brain Using [ 11 C]yohimbine PET.
- Author
-
Laurencin C, Lancelot S, Merida I, Costes N, Redouté J, Le Bars D, Boulinguez P, and Ballanger B
- Subjects
- Male, Female, Humans, Yohimbine metabolism, Norepinephrine metabolism, Positron-Emission Tomography methods, Receptors, Adrenergic, alpha-2 metabolism, Brain diagnostic imaging, Brain metabolism
- Abstract
The neurofunctional basis of the noradrenergic (NA) system and its associated disorders is still very incomplete because in vivo imaging tools in humans have been missing up to now. Here, for the first time, we use [
11 C]yohimbine in a large sample of subjects (46 healthy volunteers, 23 females, 23 males; aged 20-50) to perform direct quantification of regional alpha 2 adrenergic receptors' (α2 -ARs) availability in the living human brain. The global map shows the highest [11 C]yohimbine binding in the hippocampus, the occipital lobe, the cingulate gyrus, and the frontal lobe. Moderate binding was found in the parietal lobe, thalamus, parahippocampus, insula, and temporal lobe. Low levels of binding were found in the basal ganglia, the amygdala, the cerebellum, and the raphe nucleus. Parcellation of the brain into anatomical subregions revealed important variations in [11 C]yohimbine binding within most structures. Strong heterogeneity was found in the occipital lobe, the frontal lobe, and the basal ganglia, with substantial gender effects. Mapping the distribution of α2 -ARs in the living human brain may prove useful not only for understanding the role of the NA system in many brain functions, but also for understanding neurodegenerative diseases in which altered NA transmission with specific loss of α2 -ARs is suspected.- Published
- 2023
- Full Text
- View/download PDF
21. Noradrenaline and Movement Initiation Disorders in Parkinson's Disease: A Pharmacological Functional MRI Study with Clonidine.
- Author
-
Criaud M, Laurencin C, Poisson A, Metereau E, Redouté J, Thobois S, Boulinguez P, and Ballanger B
- Subjects
- Clonidine pharmacology, Clonidine therapeutic use, Humans, Magnetic Resonance Imaging, Movement physiology, Norepinephrine, Parkinson Disease diagnostic imaging, Parkinson Disease drug therapy
- Abstract
Slowness of movement initiation is a cardinal motor feature of Parkinson's disease (PD) and is not fully reverted by current dopaminergic treatments. This trouble could be due to the dysfunction of executive processes and, in particular, of inhibitory control of response initiation, a function possibly associated with the noradrenergic (NA) system. The implication of NA in the network supporting proactive inhibition remains to be elucidated using pharmacological protocols. For that purpose, we administered 150 μg of clonidine to 15 healthy subjects and 12 parkinsonian patients in a double-blind, randomized, placebo-controlled design. Proactive inhibition was assessed by means of a Go/noGo task, while pre-stimulus brain activity was measured by event-related functional MRI. Acute reduction in noradrenergic transmission induced by clonidine enhanced difficulties initiating movements reflected by an increase in omission errors and modulated the activity of the anterior node of the proactive inhibitory network (dorsomedial prefrontal and anterior cingulate cortices) in PD patients. We conclude that NA contributes to movement initiation by acting on proactive inhibitory control via the α2-adrenoceptor. We suggest that targeting noradrenergic dysfunction may represent a new treatment approach in some of the movement initiation disorders seen in Parkinson's disease.
- Published
- 2022
- Full Text
- View/download PDF
22. Modeling [ 11 C]yohimbine PET human brain kinetics with test-retest reliability, competition sensitivity studies and search for a suitable reference region.
- Author
-
Laurencin C, Lancelot S, Gobert F, Redouté J, Mérida I, Iecker T, Liger F, Irace Z, Greusard E, Lamberet L, Bars DL, Costes N, and Ballanger B
- Subjects
- Adult, Humans, Magnetic Resonance Imaging methods, Magnetic Resonance Imaging standards, Male, Positron-Emission Tomography methods, Reference Standards, Reproducibility of Results, Young Adult, Adrenergic alpha-2 Receptor Antagonists metabolism, Brain diagnostic imaging, Brain metabolism, Carbon Radioisotopes, Positron-Emission Tomography standards, Yohimbine metabolism
- Abstract
Previous work introduced the [
11 C]yohimbine as a suitable ligand of central α2-adrenoreceptors (α2-ARs) for PET imaging. However, reproducibility of [11 C]yohimbine PET measurements in healthy humans estimated with a simplified modeling method with reference region, as well as sensitivity of [11 C]yohimbine to noradrenergic competition were not evaluated. The objectives of the present study were therefore to fill this gap., Methods: Thirteen healthy humans underwent two [11 C]yohimbine 90-minute dynamic scans performed on a PET-MRI scanner. Seven had arterial blood sampling with metabolite assessment and plasmatic yohimbine free fraction evaluation at the first scan to have arterial input function and test appropriate kinetic modeling. The second scan was a simple retest for 6 subjects to evaluate the test-retest reproducibility. For the remaining 7 subjects the second scan was a challenge study with the administration of a single oral dose of 150 µg of clonidine 90 min before the PET scan. Parametric images of α2-ARs distribution volume ratios (DVR) were generated with two non-invasive models: Logan graphical analysis with Reference (LREF) and Simplified Reference Tissue Method (SRTM). Three reference regions (cerebellum white matter (CERWM), frontal white matter (FLWM), and corpus callosum (CC)) were tested., Results: We showed high test-retest reproducibility of DVR estimation with LREF and SRTM regardless of reference region (CC, CERWM, FLWM). The best fit was obtained with SRTMCC (r2 =0.94). Test-retest showed that the SRTMCC is highly reproducible (mean ICC>0.7), with a slight bias (-1.8%), whereas SRTMCERWM had lower bias (-0.1%), and excellent ICC (mean>0.8). Using SRTMCC , regional changes have been observed after clonidine administration with a significant increase reported in the amygdala and striatum as well as in several posterior cortical areas as revealed with the voxel-based analysis., Conclusion: The results add experimental support for the suitability of [11 C]yohimbine PET in the quantitative assessment of α2-ARs occupancy in vivo in the human brain. Trial registration EudraCT 2018-000380-82., Competing Interests: Declaration of Competing Interest The authors have no conflicts of interest to declare that are relevant to the content of this article., (Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
23. The Human Basal Ganglia Mediate the Interplay between Reactive and Proactive Control of Response through Both Motor Inhibition and Sensory Modulation.
- Author
-
Criaud M, Anton JL, Nazarian B, Longcamp M, Metereau E, Boulinguez P, and Ballanger B
- Abstract
The basal ganglia (BG) have long been known for contributing to the regulation of motor behaviour by means of a complex interplay between tonic and phasic inhibitory mechanisms. However, after having focused for a long time on phasic reactive mechanisms, it is only recently that psychological research in healthy humans has modelled tonic proactive mechanisms of control. Mutual calibration between anatomo-functional and psychological models is still needed to better understand the unclear role of the BG in the interplay between proactive and reactive mechanisms of control. Here, we implemented an event-related fMRI design allowing proper analysis of both the brain activity preceding the target-stimulus and the brain activity induced by the target-stimulus during a simple go/nogo task, with a particular interest in the ambiguous role of the basal ganglia. Post-stimulus activity was evoked in the left dorsal striatum, the subthalamus nucleus and internal globus pallidus by any stimulus when the situation was unpredictable, pinpointing its involvement in reactive, non-selective inhibitory mechanisms when action restraint is required. Pre-stimulus activity was detected in the ventral, not the dorsal, striatum, when the situation was unpredictable, and was associated with changes in functional connectivity with the early visual, not the motor, cortex. This suggests that the ventral striatum supports modulatory influence over sensory processing during proactive control.
- Published
- 2021
- Full Text
- View/download PDF
24. Inhibitory control dysfunction in parkinsonian impulse control disorders.
- Author
-
Meyer GM, Spay C, Beliakova A, Gaugain G, Pezzoli G, Ballanger B, Boulinguez P, and Cilia R
- Subjects
- Aged, Beta Rhythm, Brain Mapping, Choice Behavior, Disruptive, Impulse Control, and Conduct Disorders etiology, Electroencephalography, Executive Function, Female, Humans, Impulsive Behavior, Male, Middle Aged, Nerve Net physiopathology, Neuropsychological Tests, Parietal Lobe physiopathology, Parkinsonian Disorders complications, Psychomotor Performance, Disruptive, Impulse Control, and Conduct Disorders psychology, Inhibition, Psychological, Parkinsonian Disorders psychology
- Abstract
Impulse control disorders (ICDs) in Parkinson's disease have been associated with dysfunctions in the control of value- or reward-based responding (choice impulsivity) and abnormalities in mesocorticolimbic circuits. The hypothesis that dysfunctions in the control of response inhibition (action impulsivity) also play a role in Parkinson's disease ICDs has recently been raised, but the underlying neural mechanisms have not been probed directly. We used high-resolution EEG recordings from 41 patients with Parkinson's disease with and without ICDs to track the spectral and dynamical signatures of different mechanisms involved in inhibitory control in a simple visuomotor task involving no selection between competing responses and no reward to avoid potential confounds with reward-based decision. Behaviourally, patients with Parkinson's disease with ICDs proved to be more impulsive than those without ICDs. This was associated with decreased beta activity in the precuneus and in a region of the medial frontal cortex centred on the supplementary motor area. The underlying dynamical patterns pinpointed dysfunction of proactive inhibitory control, an executive mechanism intended to gate motor responses in anticipation of stimulation in uncertain contexts. The alteration of the cortical drive of proactive response inhibition in Parkinson's disease ICDs pinpoints the neglected role the precuneus might play in higher order executive functions in coordination with the supplementary motor area, specifically for switching between executive settings. Clinical perspectives are discussed in the light of the non-dopaminergic basis of this function., (© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
25. Resting state oscillations suggest a motor component of Parkinson's Impulse Control Disorders.
- Author
-
Spay C, Meyer G, Lio G, Pezzoli G, Ballanger B, Cilia R, and Boulinguez P
- Subjects
- Aged, Cognition physiology, Electroencephalography, Female, Humans, Impulsive Behavior physiology, Male, Middle Aged, Neuropsychological Tests, Reward, Brain physiopathology, Disruptive, Impulse Control, and Conduct Disorders physiopathology, Nerve Net physiopathology, Parkinson Disease physiopathology
- Abstract
Objectives: Impulse control disorders (ICDs) in Parkinson's disease (PD) have been associated with cognitive impulsivity and dopaminergic dysfunction and treatment. The present study tests the neglected hypothesis that the neurofunctional networks involved in motor impulsivity might also be dysfunctional in PD-ICDs., Methods: We performed blind spectral analyses of resting state electroencephalographic (EEG) data in PD patients with and without ICDs to probe the functional integrity of all cortical networks. Analyses were performed directly at the source level after blind source separation. Discrete differences between groups were tested by comparing patients with and without ICDs. Gradual dysfunctions were assessed by means of correlations between power changes and clinical scores reflecting ICD severity (QUIP score)., Results: Spectral signatures of ICDs were found in the medial prefrontal cortex, the dorsal anterior cingulate and the supplementary motor area, in the beta and gamma bands. Beta power changes in the supplementary motor area were found to predict ICDs severity., Conclusion: ICDs are associated with abnormal activity within frequency bands and cortical circuits supporting the control of motor response inhibition., Significance: These results bring to the forefront the need to consider, in addition to the classical interpretation based on aberrant mesocorticolimbic reward processing, the issue of motor impulsivity in PD-ICDs and its potential implications for PD therapy., (Copyright © 2019 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
26. Odorants: a tool to provide nonpharmacological intervention to reduce anxiety during normal and pathological aging.
- Author
-
Ballanger B, Bath KG, and Mandairon N
- Subjects
- Aging metabolism, Aging pathology, Animals, Anxiety metabolism, Anxiety psychology, Aromatherapy trends, Brain metabolism, Brain pathology, Humans, Aging drug effects, Anti-Anxiety Agents administration & dosage, Anxiety drug therapy, Aromatherapy methods, Brain drug effects, Odorants
- Abstract
Anxiety disorders represent 1 of the most common classes of psychiatric disorders. In the aging population and for patients with age-related pathology, the percentage of people suffering of anxiety is significantly elevated. Furthermore, anxiety carries with it an increased risk for a variety of age-related medical conditions, including cardiovascular disease, stroke, cognitive decline, and increased severity of motor symptoms in Parkinson's disease. A variety of anxiolytic compounds are available but often carry with them disturbing side effects that impact quality of life. Among nonmedicinal approaches to reducing anxiety, odor diffusion and aromatherapy are the most popular. In this review, we highlight the emerging perspective that the use of odorants may reduce anxiety symptoms or at least potentiate the effect of other anxiolytic approaches and may serve as an alternative form of therapy to deal with anxiety symptoms. Such approaches may be particularly beneficial in aging populations with elevated risk for these disorders. We also discuss potential neural mechanisms underlying the anxiolytic effects of odorants based on work in animal models., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
27. Functional imaging studies of Impulse Control Disorders in Parkinson's disease need a stronger neurocognitive footing.
- Author
-
Meyer GM, Spay C, Laurencin C, Ballanger B, Sescousse G, and Boulinguez P
- Subjects
- Animals, Corpus Striatum diagnostic imaging, Disruptive, Impulse Control, and Conduct Disorders diagnostic imaging, Guidelines as Topic, Humans, Parkinson Disease diagnostic imaging, Reward, Corpus Striatum physiopathology, Disruptive, Impulse Control, and Conduct Disorders physiopathology, Neuroimaging methods, Parkinson Disease physiopathology
- Abstract
Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated with dopaminergic dysfunction and treatment, but have no satisfactory therapeutic solution. While studies assessing the neurofunctional bases of ICDs are important for advancing our understanding and management of ICDs, they remain sparse and inconsistent. Based on a systematic analysis of the neuroimaging literature, the present review pinpoints various abnormalities beyond the mesocorticolimbic circuit that supports reward processing, suggesting possible dysfunction at the sensorimotor, executive and affective levels. We advocate that: 1) Future studies should use more sophisticated psychological models and behavioral designs that take into account the potentially multifaceted aspect of ICDs; this would allow a more accurate assessment of the underlying neurocognitive processes, which are not all dependent on the dopaminergic system. 2) Future neuroimaging studies should rely more strongly on task-based, event-related analyses to disentangle the various mechanisms that can be dysfunctional in ICDs. We believe these guidelines constitute a prerequisite towards distinguishing causes, correlates and individual susceptibility factors of PD patients with ICDs., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
28. Functional imaging correlates of akinesia in Parkinson's disease: Still open issues.
- Author
-
Spay C, Meyer G, Welter ML, Lau B, Boulinguez P, and Ballanger B
- Subjects
- Brain physiopathology, Gait Disorders, Neurologic physiopathology, Humans, Parkinson Disease physiopathology, Brain diagnostic imaging, Gait Disorders, Neurologic diagnostic imaging, Magnetic Resonance Imaging methods, Parkinson Disease diagnostic imaging, Positron-Emission Tomography methods
- Abstract
Akinesia is a major manifestation of Parkinson's disease (PD) related to difficulties or failures of willed movement to occur. Akinesia is still poorly understood and is not fully alleviated by standard therapeutic strategies. One reason is that the area of the clinical concept has blurred boundaries referring to confounded motor symptoms. Here, we review neuroimaging studies which, by providing access to finer-grained mechanisms, have the potential to reveal the dysfunctional brain processes that account for akinesia. It comes out that no clear common denominator could be identified across studies that are too heterogeneous with respect to the clinical/theoretical concepts and methods used. Results reveal, however, that various abnormalities within but also outside the motor and dopaminergic pathways might be associated with akinesia in PD patients. Notably, numerous yet poorly reproducible neural correlates were found in different brain regions supporting executive control by means of resting-state or task-based studies. This includes for instance the dorsolateral prefrontal cortex, the inferior frontal cortex, the supplementary motor area, the medial prefrontal cortex, the anterior cingulate cortex or the precuneus. This observation raises the issue of the multidimensional nature of akinesia. Yet, other open issues should be considered conjointly to drive future investigations. Above all, a unified terminology is needed to allow appropriate association of behavioral symptoms with brain mechanisms across studies. We adhere to a use of the term akinesia restricted to dysfunctions of movement initiation, ranging from delayed response to freezing or even total abolition of movement. We also call for targeting more specific neural mechanisms of movement preparation and action triggering with more sophisticated behavioral designs/event-related neurofunctional analyses. More work is needed to provide reliable evidence, but answering these still open issues might open up new prospects, beyond dopaminergic therapy, for managing this disabling symptom., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
29. Removing deep brain stimulation artifacts from the electroencephalogram: Issues, recommendations and an open-source toolbox.
- Author
-
Lio G, Thobois S, Ballanger B, Lau B, and Boulinguez P
- Subjects
- Animals, Artifacts, Deep Brain Stimulation instrumentation, Deep Brain Stimulation standards, Electroencephalography instrumentation, Electroencephalography standards, Humans, Signal Processing, Computer-Assisted, Software, Deep Brain Stimulation methods, Electroencephalography methods
- Abstract
A major question for deep brain stimulation (DBS) research is understanding how DBS of one target area modulates activity in different parts of the brain. EEG gives privileged access to brain dynamics, but its use with implanted patients is limited since DBS adds significant high-amplitude electrical artifacts that can completely obscure neural activity measured using EEG. Here, we systematically review and discuss the methods available for removing DBS artifacts. These include simple techniques such as oversampling, antialiasing analog filtering and digital low-pass filtering, which are necessary but typically not sufficient to fully remove DBS artifacts when each is used in isolation. We also cover more advanced methods, including techniques tracking outliers in the frequency-domain, which can be effective, but are rarely used. The reason for that is twofold: First, it requires advanced skills in signal processing since no user friendly tool for removing DBS artifacts is currently available. Second, it involves fine-tuning to avoid over-aggressive filtering. We highlight an open-source toolbox incorporating most artifact removal methods, allowing users to combine different strategies., (Copyright © 2018 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
30. Clonidine modulates the activity of the subthalamic-supplementary motor loop: evidence from a pharmacological study combining deep brain stimulation and electroencephalography recordings in Parkinsonian patients.
- Author
-
Spay C, Albares M, Lio G, Thobois S, Broussolle E, Lau B, Ballanger B, and Boulinguez P
- Subjects
- Aged, Brain Waves physiology, Cues, Electroencephalography, Female, Humans, Male, Middle Aged, Motor Cortex physiology, Neural Pathways physiology, Parkinson Disease physiopathology, Photic Stimulation, Reaction Time, Subthalamic Nucleus drug effects, Treatment Outcome, Adrenergic alpha-2 Receptor Agonists therapeutic use, Brain Waves drug effects, Clonidine therapeutic use, Deep Brain Stimulation methods, Motor Cortex drug effects, Parkinson Disease therapy, Subthalamic Nucleus physiology
- Abstract
Clonidine is an anti-hypertensive medication which acts as an alpha-adrenergic receptor agonist. As the noradrenergic system is likely to support cognitive functions including attention and executive control, other clinical uses of clonidine have recently gained popularity for the treatment of neuropsychiatric disorders like attention-deficit hyperactivity disorder or Tourette syndrome, but the mechanism of action is still unclear. Here, we test the hypothesis that the noradrenergic system regulates the activity of subthalamo-motor cortical loops, and that this influence can be modulated by clonidine. We used pharmacological manipulation of clonidine in a placebo-controlled study in combination with subthalamic nucleus-deep brain stimulation (STN-DBS) in 16 Parkinson's disease patients performing a reaction time task requiring to refrain from reacting (proactive inhibition). We recorded electroencephalographical activity of the whole cortex, and applied spectral analyses directly at the source level after advanced blind source separation. We found only one cortical source localized to the supplementary motor area (SMA) that supported an interaction of pharmacological and subthalamic stimulation. Under placebo, STN-DBS reduced proactive alpha power in the SMA, a marker of local inhibitory activity. This effect was associated with the speeding-up of movement initiation. Clonidine substantially increased proactive alpha power from the SMA source, and canceled out the benefits of STN-DBS on movement initiation. These results provide the first direct neural evidence in humans that the tonic inhibitory activity of the subthalamocortical loops underlying the control of movement initiation is coupled to the noradrenergic system, and that this activity can be targeted by pharmacological agents acting on alpha-adrenergic receptors., (© 2018 International Society for Neurochemistry.)
- Published
- 2018
- Full Text
- View/download PDF
31. Testing the physiological plausibility of conflicting psychological models of response inhibition: A forward inference fMRI study.
- Author
-
Criaud M, Longcamp M, Anton JL, Nazarian B, Roth M, Sescousse G, Strafella AP, Ballanger B, and Boulinguez P
- Subjects
- Adult, Brain Mapping, Evoked Potentials physiology, Executive Function physiology, Female, Humans, Image Processing, Computer-Assisted, Male, Models, Psychological, Oxygen blood, Photic Stimulation, Reaction Time physiology, Young Adult, Brain diagnostic imaging, Choice Behavior physiology, Inhibition, Psychological, Magnetic Resonance Imaging, Psychomotor Performance physiology
- Abstract
The neural mechanisms underlying response inhibition and related disorders are unclear and controversial for several reasons. First, it is a major challenge to assess the psychological bases of behaviour, and ultimately brain-behaviour relationships, of a function which is precisely intended to suppress overt measurable behaviours. Second, response inhibition is difficult to disentangle from other parallel processes involved in more general aspects of cognitive control. Consequently, different psychological and anatomo-functional models coexist, which often appear in conflict with each other even though they are not necessarily mutually exclusive. The standard model of response inhibition in go/no-go tasks assumes that inhibitory processes are reactively and selectively triggered by the stimulus that participants must refrain from reacting to. Recent alternative models suggest that action restraint could instead rely on reactive but non-selective mechanisms (all automatic responses are automatically inhibited in uncertain contexts) or on proactive and non-selective mechanisms (a gating function by which reaction to any stimulus is prevented in anticipation of stimulation when the situation is unpredictable). Here, we assessed the physiological plausibility of these different models by testing their respective predictions regarding event-related BOLD modulations (forward inference using fMRI). We set up a single fMRI design which allowed for us to record simultaneously the different possible forms of inhibition while limiting confounds between response inhibition and parallel cognitive processes. We found BOLD dynamics consistent with non-selective models. These results provide new theoretical and methodological lines of inquiry for the study of basic functions involved in behavioural control and related disorders., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
32. Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.
- Author
-
Strafella AP, Bohnen NI, Perlmutter JS, Eidelberg D, Pavese N, Van Eimeren T, Piccini P, Politis M, Thobois S, Ceravolo R, Higuchi M, Kaasinen V, Masellis M, Peralta MC, Obeso I, Pineda-Pardo JÁ, Cilia R, Ballanger B, Niethammer M, and Stoessl JA
- Subjects
- Humans, Molecular Imaging trends, Molecular Imaging methods, Parkinson Disease diagnosis, Parkinsonian Disorders diagnosis
- Abstract
Molecular imaging has proven to be a powerful tool for investigation of parkinsonian disorders. One current challenge is to identify biomarkers of early changes that may predict the clinical trajectory of parkinsonian disorders. Exciting new tracer developments hold the potential for in vivo markers of underlying pathology. Herein, we provide an overview of molecular imaging advances and how these approaches help us to understand PD and atypical parkinsonisms. © 2016 International Parkinson and Movement Disorder Society., (© 2016 International Parkinson and Movement Disorder Society.)
- Published
- 2017
- Full Text
- View/download PDF
33. Slowness in Movement Initiation is Associated with Proactive Inhibitory Network Dysfunction in Parkinson's Disease.
- Author
-
Criaud M, Poisson A, Thobois S, Metereau E, Redouté J, Ibarrola D, Baraduc P, Broussolle E, Strafella AP, Ballanger B, and Boulinguez P
- Subjects
- Antiparkinson Agents therapeutic use, Brain Mapping, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Motor Cortex physiopathology, Parkinson Disease drug therapy, Reaction Time, Brain physiopathology, Executive Function physiology, Inhibition, Psychological, Parkinson Disease physiopathology, Parkinson Disease psychology, Psychomotor Performance
- Abstract
Background: Impairment in initiating movements in PD might be related to executive dysfunction associated with abnormal proactive inhibitory control, a pivotal mechanism consisting in gating movement initiation in uncertain contexts., Objective: Testing this hypothesis on the basis of direct neural-based evidence., Methods: Twelve PD patients on antiparkinsonian medication and fifteen matched healthy controls performed a simple reaction time task during event-related functional MRI scanning., Results: For all subjects, the level of activation of SMA was found to predict RT on a trial-by-trial basis. The increase in movement initiation latency observed in PD patients with regard to controls was associated with pre-stimulus BOLD increases within several nodes of the proactive inhibitory network (caudate nucleus, precuneus, thalamus)., Conclusions: These results provide physiological data consistent with impaired control of proactive inhibition over motor initiation in PD. Patients would be locked into a mode of control maintaining anticipated inhibition over willed movements even when the situation does not require action restraint. The functional and neurochemical bases of brain activity associated with executive settings need to be addressed thoroughly in future studies to better understand disabling symptoms that have few therapeutic options like akinesia.
- Published
- 2016
- Full Text
- View/download PDF
34. Contribution of insula in Parkinson's disease: A quantitative meta-analysis study.
- Author
-
Criaud M, Christopher L, Boulinguez P, Ballanger B, Lang AE, Cho SS, Houle S, and Strafella AP
- Subjects
- Cerebral Cortex diagnostic imaging, Humans, Magnetic Resonance Imaging, Nerve Net diagnostic imaging, Parkinson Disease diagnostic imaging, Positron-Emission Tomography, Cerebral Cortex physiopathology, Nerve Net physiopathology, Parkinson Disease physiopathology
- Abstract
The insula region is known to be an integrating hub interacting with multiple brain networks involved in cognitive, affective, sensory, and autonomic processes. There is growing evidence suggesting that this region may have an important role in Parkinson's disease (PD). Thus, to investigate the functional organization of the insular cortex and its potential role in parkinsonian features, we used a coordinate-based quantitative meta-analysis approach, the activation likelihood estimation. A total of 132 insular foci were selected from 96 published experiments comprising the five functional categories: cognition, affective/behavioral symptoms, bodily awareness/autonomic function, sensorimotor function, and nonspecific resting functional changes associated with the disease. We found a significant convergence of activation maxima related to PD in different insular regions including anterior and posterior regions bilaterally. This study provides evidence of an important functional distribution of different domains within the insular cortex in PD, particularly in relation to nonmotor aspects, with an influence of medication effect., (© 2016 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
35. Imaging Dopamine and Serotonin Systems on MPTP Monkeys: A Longitudinal PET Investigation of Compensatory Mechanisms.
- Author
-
Ballanger B, Beaudoin-Gobert M, Neumane S, Epinat J, Metereau E, Duperrier S, Broussolle E, Thobois S, Bonnefoi F, Tourvielle C, Lavenne F, Costes N, Lebars D, Zimmer L, Sgambato-Faure V, and Tremblay L
- Subjects
- Animals, Corpus Striatum diagnostic imaging, Corpus Striatum metabolism, Corpus Striatum pathology, Dopaminergic Neurons metabolism, Dopaminergic Neurons pathology, Longitudinal Studies, Macaca fascicularis, Male, Parkinsonian Disorders metabolism, Parkinsonian Disorders pathology, Serotonergic Neurons metabolism, Serotonergic Neurons pathology, Dopaminergic Neurons diagnostic imaging, Parkinsonian Disorders diagnostic imaging, Positron-Emission Tomography trends, Serotonergic Neurons diagnostic imaging
- Abstract
It is now widely accepted that compensatory mechanisms are involved during the early phase of Parkinson's disease (PD) to delay the expression of motor symptoms. However, the neurochemical mechanisms underlying this presymptomatic period are still unclear. Here, we measured in vivo longitudinal changes of both the dopaminergic and serotonergic systems in seven asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated monkeys (when motor symptoms are less apparent) using PET. We used the progressively MPTP-intoxicated monkey model that expresses recovery from motor symptoms to study the changes in dopamine synthesis ([(18)F]DOPA), dopamine D2/D3 receptors ([(11)C]raclopride), and serotonin transporter (11)C-N,N-dimethyl-2-(-2-amino-4-cyanophenylthio) benzylamine ([(11)C]DASB) and serotonin 1A receptor ([(18)F]MPPF) levels between four different states (baseline, early symptomatic, full symptomatic and recovered). During the early symptomatic state, we observed increases of [(18)F]DOPA uptake in the anterior putamen, [(11)C]raclopride binding in the posterior striatum, and 2'-methoxyphenyl-(N-2'-pyridinyl)-p-[(18)F]fluoro-benzamidoethylpiperazine [(18)F]MPPF uptake in the orbitofrontal cortex and dorsal ACC. After recovery from motor symptoms, the results mainly showed decreased [(11)C]raclopride binding in the anterior striatum and limbic ACC. In addition, our findings supported the importance of pallidal dopaminergic neurotransmission in both the early compensatory mechanisms and the functional recovery mechanisms, with reduced aromatic L-amino acid decarboxylase (AAAD) activity closely related to the appearance or perseveration of motor symptoms. In parallel, this study provides preliminary evidence of the role of the serotonergic system in compensatory mechanisms. Nonetheless, future studies are needed to determine whether there are changes in SERT availability in the early symptomatic state and if [(18)F]MPPF PET imaging might be a promising biomarker of early degenerative changes in PD., Significance Statement: The present research provides evidence of the potential of combining a multitracer PET imaging technique and a longitudinal protocol applied on a progressively 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated monkey model to further elucidate the nature of the compensatory mechanisms involved in the preclinical period of Parkinson's disease (PD). In particular, by investigating the dopaminergic and serotonergic changes both presynaptically and postsynaptically at four different motor states (baseline, early symptomatic, full symptomatic, and recovered), this study has allowed us to identify putative biomarkers for future therapeutic interventions to prevent and/or delay disease expression. For example, our findings suggest that the external pallidum could be a new target for cell-based therapies to reduce PD symptoms., (Copyright © 2016 the authors 0270-6474/16/361578-13$15.00/0.)
- Published
- 2016
- Full Text
- View/download PDF
36. Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate.
- Author
-
Beaudoin-Gobert M, Epinat J, Météreau E, Duperrier S, Neumane S, Ballanger B, Lavenne F, Liger F, Tourvielle C, Bonnefoi F, Costes N, Bars DL, Broussolle E, Thobois S, Tremblay L, and Sgambato-Faure V
- Subjects
- Aniline Compounds, Animals, Antiparkinson Agents therapeutic use, Brain diagnostic imaging, Brain pathology, Brain Mapping, Chlorocebus aethiops, Disease Models, Animal, Dopamine Agents toxicity, Female, Levodopa therapeutic use, MPTP Poisoning chemically induced, MPTP Poisoning drug therapy, Macaca fascicularis, Male, N-Methyl-3,4-methylenedioxyamphetamine toxicity, Nortropanes, Radionuclide Imaging, Serotonin Agents toxicity, Sulfides, Dopamine metabolism, MPTP Poisoning physiopathology, Mental Disorders etiology, Serotonin metabolism
- Abstract
Serotonergic (5-HT) neurons degenerate in Parkinson's disease. To determine the role of this 5-HT injury-besides the dopaminergic one in the parkinsonian symptomatology-we developed a new monkey model exhibiting a double dopaminergic/serotonergic lesion by sequentially using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 3,4-methylenedioxy-N-methamphetamine (MDMA, better known as ecstasy). By positron emission tomography imaging and immunohistochemistry, we demonstrated that MDMA injured 5-HT nerve terminals in the brain of MPTP monkeys. Unexpectedly, this injury had no impact on tremor or on bradykinesia, but altered rigidity. It abolished the l-DOPA-induced dyskinesia and neuropsychiatric-like behaviours, without altering the anti-parkinsonian response. These data demonstrate that 5-HT fibres play a critical role in the expression of both motor and non-motor symptoms in Parkinson's disease, and highlight that an imbalance between the 5-HT and dopaminergic innervating systems is involved in specific basal ganglia territories for different symptoms., (© The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
37. Interaction of noradrenergic pharmacological manipulation and subthalamic stimulation on movement initiation control in Parkinson's disease.
- Author
-
Albares M, Thobois S, Favre E, Broussolle E, Polo G, Domenech P, Boulinguez P, and Ballanger B
- Subjects
- Adrenergic alpha-2 Receptor Agonists therapeutic use, Aged, Combined Modality Therapy methods, Female, Humans, Male, Middle Aged, Parkinson Disease physiopathology, Psychomotor Performance drug effects, Psychomotor Performance physiology, Reaction Time drug effects, Clonidine therapeutic use, Deep Brain Stimulation, Movement drug effects, Movement physiology, Parkinson Disease drug therapy, Parkinson Disease therapy, Subthalamic Nucleus physiology
- Abstract
Background: Slowness in movement initiation (akinesia) is a cardinal feature of Parkinson's disease (PD), which is still poorly understood. Notably, akinesia is restored by subthalamic nucleus deep brain stimulation (STN-DBS) but not fully reversed by current dopaminergic treatments. It was recently suggested that this disorder is of executive nature (related to inhibitory control of response) and of non-dopaminergic origin (possibly noradrenergic)., Objective: To test the double hypothesis that: 1) the ability to control movement initiation is modified by noradrenergic neurotransmission modulation, and 2) this effect is mediated by the regulation of STN activity., Methods: Sixteen STN-DBS PD patients were enrolled in a placebo-controlled study investigating the effects of noradrenergic attenuation by clonidine (∝2-adrenergic receptor agonist). Movement initiation latency was assessed by means of a cue-target reaction time task. Patients, who remained on their chronic dopaminergic medication, were tested on four sessions: two with placebo (ON- or OFF-DBS), and two with a 150 μg oral dose of clonidine (ON- or OFF-DBS)., Results: In the OFF stimulation condition, patients were locked into a mode of control maintaining inappropriate response inhibition. This dysfunctional executive setting was overcome by STN-DBS. Clonidine, however, was found to impair specifically the ability to release inhibitory control in the ON-DBS state., Conclusions: Overall our results suggest an important implication of the noradrenergic system in the pathophysiology of akinesia in PD. Reducing the noradrenergic "tonus" may even block the positive action of STN-DBS on akinesia, suggesting, at least by part, a noradrenergic-dependent STN-DBS efficiency., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
38. A multi-atlas based method for automated anatomical Macaca fascicularis brain MRI segmentation and PET kinetic extraction.
- Author
-
Ballanger B, Tremblay L, Sgambato-Faure V, Beaudoin-Gobert M, Lavenne F, Le Bars D, and Costes N
- Subjects
- Animals, Brain physiology, Female, Kinetics, Macaca fascicularis, Magnetic Resonance Imaging, Male, Positron-Emission Tomography, Anatomy, Artistic, Atlases as Topic, Brain anatomy & histology, Image Processing, Computer-Assisted methods, Multimodal Imaging methods
- Abstract
Unlabelled: MRI templates and digital atlases are needed for automated and reproducible quantitative analysis of non-human primate PET studies. Segmenting brain images via multiple atlases outperforms single-atlas labelling in humans. We present a set of atlases manually delineated on brain MRI scans of the monkey Macaca fascicularis. We use this multi-atlas dataset to evaluate two automated methods in terms of accuracy, robustness and reliability in segmenting brain structures on MRI and extracting regional PET measures., Methods: Twelve individual Macaca fascicularis high-resolution 3DT1 MR images were acquired. Four individual atlases were created by manually drawing 42 anatomical structures, including cortical and sub-cortical structures, white matter regions, and ventricles. To create the MRI template, we first chose one MRI to define a reference space, and then performed a two-step iterative procedure: affine registration of individual MRIs to the reference MRI, followed by averaging of the twelve resampled MRIs. Automated segmentation in native space was obtained in two ways: 1) Maximum probability atlases were created by decision fusion of two to four individual atlases in the reference space, and transformation back into the individual native space (MAXPROB)(.) 2) One to four individual atlases were registered directly to the individual native space, and combined by decision fusion (PROPAG). Accuracy was evaluated by computing the Dice similarity index and the volume difference. The robustness and reproducibility of PET regional measurements obtained via automated segmentation was evaluated on four co-registered MRI/PET datasets, which included test-retest data., Results: Dice indices were always over 0.7 and reached maximal values of 0.9 for PROPAG with all four individual atlases. There was no significant mean volume bias. The standard deviation of the bias decreased significantly when increasing the number of individual atlases. MAXPROB performed better when increasing the number of atlases used. When all four atlases were used for the MAXPROB creation, the accuracy of morphometric segmentation approached that of the PROPAG method. PET measures extracted either via automatic methods or via the manually defined regions were strongly correlated, with no significant regional differences between methods. Intra-class correlation coefficients for test-retest data were over 0.87., Conclusions: Compared to single atlas extractions, multi-atlas methods improve the accuracy of region definition. They also perform comparably to manually defined regions for PET quantification. Multiple atlases of Macaca fascicularis brains are now available and allow reproducible and simplified analyses., (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
39. A functional magnetic resonance imaging study of pathophysiological changes responsible for mirror movements in Parkinson's disease.
- Author
-
Poisson A, Ballanger B, Metereau E, Redouté J, Ibarolla D, Comte JC, Bernard HG, Vidailhet M, Broussolle E, and Thobois S
- Subjects
- Aged, Dyskinesias complications, Female, Humans, Male, Middle Aged, Parkinson Disease complications, Dyskinesias physiopathology, Magnetic Resonance Imaging, Parkinson Disease physiopathology
- Abstract
Mirror movements correspond to involuntary movements observed in the limb contralateral to the one performing voluntary movement. They can be observed in Parkinson's disease (PD) but their pathophysiology remains unclear. The present study aims at identifying their neural correlates in PD using functional magnetic resonance imaging. Ten control subjects and 14-off drug patients with asymmetrical right-sided PD were included (8 with left-sided mirror movements during right-hand movements, and 6 without mirror movements). Between-group comparisons of BOLD signal were performed during right-hand movements and at rest (p<0.005 uncorrected). The comparison between PD patients with and without mirror movements showed that mirror movements were associated with an overactivation of the insula, precuneus/posterior cingulate cortex bilaterally and of the left inferior frontal cortex and with a deactivation of the right dorsolateral prefrontal cortex, medial prefrontal cortex, and pre-supplementary motor area and occipital cortex. These data suggest that mirror movements in Parkinson's disease are promoted by: 1- a deactivation of the non-mirroring inhibitory network (dorsolateral prefrontal cortex, pre-supplementary motor area); 2- an overactivation of prokinetic areas (notably the insula). The concomitant overactivation of a proactive inhibitory network (including the posterior cingulate cortex and precuneus) could reflect a compensatory inhibition of mirror movements.
- Published
- 2013
- Full Text
- View/download PDF
40. Effects of dopamine and serotonin antagonist injections into the striatopallidal complex of asymptomatic MPTP-treated monkeys.
- Author
-
Neumane S, Mounayar S, Jan C, Epinat J, Ballanger B, Costes N, Féger J, Thobois S, François C, Sgambato-Faure V, and Tremblay L
- Subjects
- Animals, Chlorocebus aethiops, Corpus Striatum physiopathology, Macaca fascicularis, Male, Microinjections, Corpus Striatum drug effects, Dopamine Antagonists pharmacology, Flupenthixol pharmacology, Mianserin pharmacology, Parkinsonian Disorders physiopathology, Serotonin Antagonists pharmacology
- Abstract
The cardinal symptoms of Parkinson's disease (PD), akinesia, rigidity and tremor, are only observed when the striatal level of dopamine (DA) is decreased by 60-80%. It is likely that compensatory mechanisms during the early phase of DA depletion delay the appearance of motor symptoms. In a previous study, we proposed a new PD monkey model with progressive MPTP intoxication. Monkeys developed all of the motor symptoms and then fully recovered despite a large DA cell loss in the substantia nigra (SN). Compensatory mechanisms certainly help to offset the dysfunction induced by the DA lesion, facilitating motor recovery in this model. Neurotransmitter measurements in the striatal sensorimotor and associative/limbic territories of these monkeys subsequently revealed that DA and serotonin (5-HT) could play a role in recovery mechanisms. To try to determine the involvement of these neurotransmitters in compensatory mechanisms, we performed local injections of DA and 5-HT antagonists (cis-flupenthixol and mianserin, respectively) into these two striatal territories and into the external segment of the globus pallidus (GPe). Injections were performed on monkeys that were in an asymptomatic state after motor recovery. Most parkinsonian motor symptoms reappeared in animals with DA antagonist injections either in sensorimotor, associative/limbic striatal territories or in the GPe. In contrast to the effects with DA antagonist, there were mild parkinsonian effects with 5-HT antagonist, especially after injections in sensorimotor territories of the striatum and the GPe. These results support a possible, but slight, involvement of 5-HT in compensatory mechanisms and highlight the possible participation of 5-HT in some behavioural disorders. Furthermore, these results support the notion that the residual DA in the different striatal territories and the GPe could be involved in important mechanisms of compensation in PD., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
41. Functional imaging of non-motor signs in Parkinson's disease.
- Author
-
Ballanger B, Poisson A, Broussolle E, and Thobois S
- Subjects
- Animals, Humans, Magnetic Resonance Imaging methods, Parkinson Disease epidemiology, Positron-Emission Tomography methods, Tomography, Emission-Computed, Single-Photon methods, Diagnostic Imaging methods, Parkinson Disease diagnosis, Parkinson Disease physiopathology
- Abstract
Non-motor signs encountered in Parkinson's disease consist in a heterogeneous group of manifestations including hyposmia, pain, fatigue, sleep disorders, neuropsychic disorders. Functional imaging techniques provide an invaluable method to understand their pathophysiology, allowing us to study the abnormalities of brain metabolism or perfusion associated with these manifestations or the underlying dysfunction of different neurotransmission systems. The present paper covers the recent advances provided by functional imaging in this area., (Copyright © 2011 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
42. Proactive inhibitory control of response as the default state of executive control.
- Author
-
Criaud M, Wardak C, Ben Hamed S, Ballanger B, and Boulinguez P
- Abstract
Refraining from reacting does not only involve reactive inhibitory mechanisms. It was recently found that inhibitory control also relies strongly on proactive mechanisms. However, since most available studies have focused on reactive stopping, little is known about how proactive inhibition of response is implemented. Two behavioral experiments were conducted to identify the temporal dynamics of this executive function. They manipulated respectively the time during which inhibitory control must be sustained until a stimulus occurs, and the time limit allowed to set up inhibition before a stimulus occurs. The results show that inhibitory control is not set up after but before instruction, and is not transient and sporadic but sustained across time. Consistent with our previous neuroimaging findings, these results suggest that proactive inhibition of response is the default mode of executive control. This implies that top-down control of sensorimotor reactivity would consist of a temporary release (up to several seconds), when appropriate (when the environment becomes predictable), of the default locking state. This conclusion is discussed with regard to current anatomo-functional models of inhibitory control, and to methodological features of studies of attention and sensorimotor control.
- Published
- 2012
- Full Text
- View/download PDF
43. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease.
- Author
-
Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, Tremblay L, Sgambato-Faure V, Broussolle E, and Thobois S
- Subjects
- Adult, Aged, Aminopyridines pharmacokinetics, Brain diagnostic imaging, Brain drug effects, Female, Fluorine Radioisotopes, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Parkinson Disease diagnostic imaging, Piperazines pharmacokinetics, Positron-Emission Tomography, Serotonin Antagonists pharmacokinetics, Depression diagnostic imaging, Depression etiology, Parkinson Disease complications, Receptor, Serotonin, 5-HT1A metabolism
- Abstract
Depression is frequent in Parkinson's disease, but its pathophysiology remains unclear. Two recent studies have investigated the role of serotonergic system at the presynaptic level. The objective of the present study was to use positron emission tomography and [(18)F]MPPF to investigate the role of postsynaptic serotonergic system dysfunction in the pathophysiology of depression in Parkinson's disease. Four parkinsonian patients with depression and 8 parkinsonian patients without depression were enrolled. Each patient underwent a scan using [(18)F]MPPF, a selective serotonin 1A receptor antagonist. Voxel-by-voxel statistical comparison of [(18)F]MPPF uptake of the 2 groups of parkinsonian patients and with 7 matched normal subjects was made using statistical parametric mapping (P uncorrected < .001). Compared with nondepressed parkinsonian patients, depressed patients exhibited reduced tracer uptake in the left hippocampus, the right insula, the left superior temporal cortex, and the orbitofrontal cortex. Compared with controls, nondepressed parkinsonian patients presented reduced [(18)F]MPPF uptake bilaterally in the inferior frontal cortex as well as in the right ventral striatum and insula. Compared with controls, [(18)F]MPPF uptake was decreased in depressed parkinsonian patients in the left dorsal anterior cingulate and orbitofrontal cortices, in the right hippocampic region, and in the temporal cortex. The present imaging study suggests that abnormalities in serotonin 1A receptor neurotransmission in the limbic system may be involved in the neural mechanisms underlying depression in patients with Parkinson's disease., (Copyright © 2011 Movement Disorder Society.)
- Published
- 2012
- Full Text
- View/download PDF
44. Contact dependent reproducible hypomania induced by deep brain stimulation in Parkinson's disease: clinical, anatomical and functional imaging study.
- Author
-
Ulla M, Thobois S, Llorca PM, Derost P, Lemaire JJ, Chereau-Boudet I, de Chazeron I, Schmitt A, Ballanger B, Broussolle E, and Durif F
- Subjects
- Aged, Attention physiology, Bipolar Disorder diagnosis, Bipolar Disorder diagnostic imaging, Brain blood supply, Brain diagnostic imaging, Brain physiopathology, Brain Mapping methods, Deep Brain Stimulation methods, Female, Humans, Implantable Neurostimulators, Magnetic Resonance Imaging methods, Male, Middle Aged, Parkinson Disease complications, Parkinson Disease diagnostic imaging, Parkinson Disease physiopathology, Positron-Emission Tomography methods, Psychomotor Performance physiology, Substantia Nigra diagnostic imaging, Substantia Nigra physiopathology, Subthalamic Nucleus diagnostic imaging, Subthalamic Nucleus surgery, Tomography, X-Ray Computed methods, Bipolar Disorder etiology, Bipolar Disorder physiopathology, Deep Brain Stimulation adverse effects, Parkinson Disease therapy, Subthalamic Nucleus physiopathology
- Abstract
Hypomanic symptoms depending on anatomical location of contacts are reported in patients with Parkinson's disease (PD) treated by deep brain stimulation (DBS) of the subthalamic nucleus (STN). However, the underlying cortical and subcortical dysfunction is debated. In this study, five PD patients implanted with DBS-STN who presented with reversible and reproducible hypomanic symptoms after stimulation of specific 'manic' contacts were investigated. Hypomanic symptoms were assessed using the Bech and Rafaelsen Mania Scale (MAS). Three dimensional anatomical location of 'euthymic' and 'manic' contacts, after matching the postoperative CT scan with the preoperative stereotactic MRI, and a H(2)(15)O positron emission tomography (PET) study testing 'euthymic' and 'manic' contacts, were performed. Under 'euthymic' conditions, MAS score (mean±SD) was 0.6±0.5 compared with 7.8±3.1 under 'manic' conditions. Nine of 10 'manic' contacts were located in the substantia nigra, mainly in its ventral part. PET showed that hypomania was associated with strong asymmetrical cerebral activation involving preferentially the right hemisphere and was mediated by activation of the anterior cingulate and medial prefrontal cortex. The present study demonstrates the role of the subcortical structures in the genesis of hypomania in PD patients treated with DBS and stresses the involvement of the substantia nigra.
- Published
- 2011
- Full Text
- View/download PDF
45. Serotonin 2A receptors and visual hallucinations in Parkinson disease.
- Author
-
Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, and Fox SH
- Subjects
- Aged, Brain diagnostic imaging, Brain metabolism, Brain Mapping, Case-Control Studies, Female, Hallucinations diagnostic imaging, Humans, Male, Middle Aged, Parkinson Disease diagnostic imaging, Pilot Projects, Positron-Emission Tomography, Pyrimidinones, Receptor, Serotonin, 5-HT2A genetics, Serotonin metabolism, Serotonin Antagonists, Temporal Lobe diagnostic imaging, Temporal Lobe metabolism, Temporal Lobe physiopathology, Visual Cortex diagnostic imaging, Visual Cortex metabolism, Visual Cortex physiopathology, Visual Pathways diagnostic imaging, Visual Pathways metabolism, Visual Pathways physiopathology, Brain physiopathology, Hallucinations etiology, Hallucinations physiopathology, Parkinson Disease complications, Parkinson Disease physiopathology, Receptor, Serotonin, 5-HT2A metabolism
- Abstract
Background: Complex visual hallucinations (VHs) occur in several pathologic conditions; however, the neural mechanisms underlying these symptoms remain unclear. Although dopamine may have a role, indirect evidence indicates that serotonin may also contribute to the pathogenesis of complex VHs, probably via involvement of the serotonin 2 receptor., Objective: To examine for the first time in vivo changes in serotonin 2A receptor neurotransmission among patients having Parkinson disease (PD) with VHs., Design: Case-control study., Setting: Academic research., Patients: Seven patients having PD with VHs and 7 age-matched patients having PD without VHs were recruited., Main Outcome Measures: We used the selective serotonin 2A receptor ligand setoperone F 18 during positron emission tomography among nondemented patients having PD with VHs., Results: Patients having PD with VHs demonstrate increased serotonin 2A receptor binding in the ventral visual pathway (including the bilateral inferooccipital gyrus, right fusiform gyrus, and inferotemporal cortex) as well as the bilateral dorsolateral prefrontal cortex, medial orbitofrontal cortex, and insula., Conclusions: This pilot study provides the first in vivo evidence suggesting a role for serotonin 2A receptors in mediating VHs via the ventral visual pathway in PD. Treatment studies should be performed using selective serotonin 2A receptor antagonists, which have important implications for the clinical management of VHs and psychosis in PD.
- Published
- 2010
- Full Text
- View/download PDF
46. Stimulation of the subthalamic nucleus and impulsivity: release your horses.
- Author
-
Ballanger B, van Eimeren T, Moro E, Lozano AM, Hamani C, Boulinguez P, Pellecchia G, Houle S, Poon YY, Lang AE, and Strafella AP
- Subjects
- Aged, Brain Mapping, Cerebrovascular Circulation physiology, Female, Humans, Impulsive Behavior diagnostic imaging, Impulsive Behavior etiology, Inhibition, Psychological, Male, Middle Aged, Neuropsychological Tests, Parkinson Disease complications, Parkinson Disease diagnostic imaging, Parkinson Disease therapy, Positron-Emission Tomography methods, Reaction Time physiology, Severity of Illness Index, Statistics as Topic, Choice Behavior physiology, Deep Brain Stimulation methods, Impulsive Behavior therapy, Subthalamic Nucleus physiology
- Abstract
Objective: In Parkinson disease (PD) patients, deep brain stimulation (DBS) of the subthalamic nucleus (STN) may contribute to certain impulsive behavior during high-conflict decisions. A neurocomputational model of the basal ganglia has recently been proposed that suggests this behavioral aspect may be related to the role played by the STN in relaying a "hold your horses" signal intended to allow more time to settle on the best option. The aim of the present study was 2-fold: 1) to extend these observations by providing evidence that the STN may influence and prevent the execution of any response even during low-conflict decisions; and 2) to identify the neural correlates of this effect., Methods: We measured regional cerebral blood flow during a Go/NoGo and a control (Go) task to study the motor improvement and response inhibition deficits associated with STN-DBS in patients with PD., Results: Although it improved Unified Parkinson Disease Rating Scale motor ratings and induced a global decrease in reaction time during task performance, STN-DBS impaired response inhibition, as revealed by an increase in commission errors in NoGo trials. These behavioral effects were accompanied by changes in synaptic activity consisting of a reduced activation in the cortical networks responsible for reactive and proactive response inhibition., Interpretation: The present results suggest that although it improves motor functions in PD patients, modulation of STN hyperactivity with DBS may tend at the same time to favor the appearance of impulsive behavior by acting on the gating mechanism involved in response initiation.
- Published
- 2009
- Full Text
- View/download PDF
47. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?
- Author
-
van Eimeren T, Ballanger B, Pellecchia G, Miyasaki JM, Lang AE, and Strafella AP
- Subjects
- Benzothiazoles pharmacology, Benzothiazoles therapeutic use, Dopamine Agonists therapeutic use, Frontal Lobe physiopathology, Humans, Levodopa pharmacology, Levodopa therapeutic use, Magnetic Resonance Imaging, Male, Middle Aged, Parkinson Disease complications, Parkinson Disease drug therapy, Parkinson Disease physiopathology, Pramipexole, Psychomotor Performance drug effects, Psychomotor Performance physiology, Risk-Taking, Dopamine Agonists pharmacology, Frontal Lobe drug effects, Gambling psychology, Parkinson Disease psychology, Reward
- Abstract
The neurobehavioral underpinnings of pathological gambling are not well understood. Insight might be gained by understanding pharmacological effects on the reward system in patients with Parkinson's disease (PD). Treatment with dopamine agonists (DAs) has been associated with pathological gambling in PD patients. However, how DAs are involved in the development of this form of addiction is unknown. We tested the hypothesis that tonic stimulation of dopamine receptors specifically desensitizes the dopaminergic reward system by preventing decreases in dopaminergic transmission that occurs with negative feedback. Using functional magnetic resonance imaging, we studied PD patients during three sessions of a probabilistic reward task in random order: off medication, after levodopa (LD) treatment, and after an equivalent dose of DA (pramipexole). For each trial, a reward prediction error value was computed using outcome, stake, and probability. Pramipexole specifically changed activity of the orbitofrontal cortex (OFC) in two ways that were both associated with increased risk taking in an out-of-magnet task. Outcome-induced activations were generally higher with pramipexole compared with LD or off medication. In addition, only pramipexole greatly diminished trial-by-trial correlation with reward prediction error values. Further analysis yielded that this resulted mainly from impaired deactivation in trials with negative errors in reward prediction. We propose that DAs prevent pauses in dopamine transmission and thereby impair the negative reinforcing effect of losing. Our findings raise the question of whether pathological gambling may in part stem from an impaired capacity of the OFC to guide behavior when facing negative consequences.
- Published
- 2009
- Full Text
- View/download PDF
48. Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson's disease: a [(15)O] H2O PET study.
- Author
-
Ballanger B, Lozano AM, Moro E, van Eimeren T, Hamani C, Chen R, Cilia R, Houle S, Poon YY, Lang AE, and Strafella AP
- Subjects
- Aged, Electrodes, Implanted, Humans, Image Interpretation, Computer-Assisted, Male, Motor Skills physiology, Oxygen Radioisotopes, Parkinson Disease diagnostic imaging, Parkinson Disease physiopathology, Pedunculopontine Tegmental Nucleus diagnostic imaging, Pedunculopontine Tegmental Nucleus physiopathology, Positron-Emission Tomography, Radiopharmaceuticals, Brain Mapping, Cerebrovascular Circulation physiology, Deep Brain Stimulation methods, Parkinson Disease therapy, Pedunculopontine Tegmental Nucleus blood supply
- Abstract
Patients with advanced Parkinson's disease (PD) develop disabling axial symptoms, including gait disturbances, freezing and postural instability poorly responsive to levodopa replacement therapy. The pedunculopontine nucleus (PPN) is involved in locomotion, control of posture, and behavioral states [i.e. wakefulness, rapid eye movement sleep]. Recent reports suggested that PPN modulation with deep brain stimulation (DBS) may be beneficial in the treatment of axial symptoms. However, the mechanisms underlying these effects are still unknown. We used [(15)O] H(2)O PET to investigate regional cerebral blood flow in three patients with advanced PD who underwent a new experimental surgical procedure with implantation of unilateral PPN-DBS. Patients were studied Off-medication with stimulator Off and On, both at rest and during a self-paced alternating motor task of the lower limbs. We used SPM2 for imaging data analysis, threshold P < 0.05 corrected at the cluster level. Stimulation induced significant regional cerebral blood flow increment in subcortical regions such as the thalamus (P < 0.006), cerebellum (P < 0.001), and midbrain region (P < 0.001) as well as different cortical areas involving medial sensorimotor cortex extending into caudal supplementary motor area (BA 4/6; P < 0.001). PPN-DBS in advanced PD resulted in blood flow and presumably neuronal activity changes in subcortical and cortical areas involved in balance and motor control, including the mesencephalic locomotor region (e.g. PPN) and closely interconnected structures within the cerebello-(rubro)-thalamo-cortical circuit. Whether these findings are associated with the DBS-PPN clinical effect remains to be proven. However, they suggest that PPN modulation may induce functional changes in neural networks associated with the control of lower limb movements., (2009 Wiley-Liss, Inc.)
- Published
- 2009
- Full Text
- View/download PDF
49. Top-down control of saccades as part of a generalized model of proactive inhibitory control.
- Author
-
Ballanger B
- Subjects
- Animals, Nerve Net physiology, Neurons physiology, Superior Colliculi cytology, Superior Colliculi physiology, Models, Neurological, Neural Inhibition physiology, Saccades physiology, Visual Fields physiology
- Abstract
Lo and colleagues have recently described a recurrent network model of inhibitory control of saccadic eye movements based on neurophysiological observations in the frontal eye field (FEF) and superior colliculus (SC) of rhesus monkeys. This model emphasizes the proactive, inhibition-based, tonic neuronal activity that prevents the eye from moving in a countermanding paradigm. In this review I discuss the model with respect to existing literature that the authors did not mention, suggesting that proactive inhibitory control extends far beyond saccadic control and provides an interesting framework to interpret several attentional and movement disorders in humans.
- Published
- 2009
- Full Text
- View/download PDF
50. PET functional imaging of deep brain stimulation in movement disorders and psychiatry.
- Author
-
Ballanger B, Jahanshahi M, Broussolle E, and Thobois S
- Subjects
- Brain diagnostic imaging, Humans, Mental Disorders diagnostic imaging, Mental Disorders physiopathology, Movement Disorders diagnostic imaging, Movement Disorders physiopathology, Brain physiology, Deep Brain Stimulation, Mental Disorders surgery, Movement Disorders surgery, Positron-Emission Tomography
- Abstract
Deep brain stimulation (DBS) represents a major advance in the treatment of various severe movement disorders or neuropsychiatric diseases. Our understanding of the mechanism of action of this surgical treatment has greatly benefited from functional imaging studies. Most of these studies have been conducted in patients with Parkinson's disease (PD) treated by bilateral subthalamic nucleus (STN) stimulation. These studies have notably underlined the fact that STN stimulation influences motor, limbic, or associative cortical-subcortical loops in various (sometimes contradictory) ways. We present an up-to-date review of the information provided by functional imaging studies in surgery for PD, dystonia, tremor, as well as in psychiatric disorders such as depression or obsessive-compulsive disorder. On the basis of this information, proposed mechanisms of action of DBS are discussed, as well as the need for additional approaches such as improved anatomical localization of the contact used for stimulation or a better understanding of the electrical distribution around the electrode.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.